CareDx Announces Cibiltech Initiates CIBIL Study Using iBox Artificial Intelligence to Monitor Kidney Transplant Patients

CareDx, Inc. The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers announced that its strategic partner, Cibiltech, a French MedTech company that develops artificial intelligence-based products for predictive medicine, has initiated the CIBIL clinical trial to evaluate the performance of iBox artificial intelligence (AI) as a prognostic measure of organ survival in kidney transplant patients.

The CIBIL “Clinical Impact of the iBox as an Early Intervention tooL” trial is a prospective randomized controlled trial being conducted internationally with 450 patients to evaluate the clinical and health economic benefits of using iBox to predict allograft survival in the follow-up of kidney transplanted patients (NCT05112315). iBox has been previously validated by the Paris Transplant Group in a seminal AI paper for transplantation in the British Medical Journal.

“The CIBIL trial represents a key milestone in CareDx’s partnership with Cibiltech as we continue to evolve our multimodality pipeline with iBox and its prognostic capabilities to assess organ graft survival,” said Reg Seeto, CEO and President of CareDx. “We are seeing the benefits of incorporating AI into our OKRA study, which includes the iBox technology as a predictive tool alongside multimodality testing with our AlloSure and AlloMap services. We look forward to the results of both CIBIL and OKRA, and to making iBox more widely available to clinicians in the United States as an additional clinical tool.”

Recommended AI News: Tafi Partners with Coca-Cola to Bring a Taste of Space to Samsung AR Emoji with New Digital Apparel Collection

CareDx is a minority owner of Cibiltech and holds exclusive rights to commercialize iBox in the United States. iBox is an algorithm developed by the Paris Transplant Group, which determines the probability of graft survival three, five, and seven years after evaluation. The OKRA (Outcomes of KidneyCare in Renal Allografts) is a multicenter, prospective, observational registry designed to measure outcomes of kidney transplant recipients managed with CareDx’s multimodality assessment of graft health including AlloSure donor-derived cell-free DNA (dd-cfDNA), AlloMap kidney gene expression profiling, and prognostic graft assessment using iBox.

“We are excited to initiate the CIBIL study to assess the clinical and health economic benefits of using the iBox AI algorithm as an early intervention monitoring tool for kidney transplant patients worldwide,” said Stephane Tholander, CEO of Cibiltech. “We look forward to continuing our partnership with CareDx to incorporate iBox into its pipeline of offerings so that clinicians have additional tools to help improve long-term transplant health outcomes.”

Recommended AI News: Cellwize Introduces a RAN Service Management Orchestration Solution for the Hybrid ORAN Era, Bringing Mobile Operators Closer to Realizing an ORAN Future

[To share your insights with us, please write to sghosh@martechseries.com]